Skip to main content
SpringerLink
Log in

Holistic Preferences for 1-Year Health Profiles Describing Fluctuations in Health

The Case of Chronic Obstructive Pulmonary Disease

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Background: There are few empirical studies on the valuation of health profiles that describe the short-term fluctuations of chronic diseases.

Objective: This study aimed to value chronic obstructive pulmonary disease (COPD) health profiles, which describe the health of these patients over the course of 1 year from a societal perspective.

Methods: We developed 16 COPD health profiles. Each profile combined a description of the severity of COPD during the stable phase with a description of the exacerbation profile in terms of severity, frequency and duration. These profiles were valued by a representative sample of 239 Dutch adults using the visual analogue scale (VAS) and time trade-off (TTO) methods. Value functions were estimated using random effects regression analysis.

Results: Both VAS and TTO values consistently decreased as severity of the COPD profiles increased. Estimated TTO values ranged from 0.97 for mild COPD without exacerbations to 0.43 for very severe COPD with one non-serious and one serious exacerbation per year. The estimated decrements in TTO values ranged from 0.010 for having one non-serious exacerbation to 0.088 for having one non-serious plus one serious exacerbation per year.

Conclusions: The value function may be an alternative way to model the joint impact of COPD severity and exacerbations on utility values in health economic modelling studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Fig. 3
Table II

Similar content being viewed by others

References

  1. Bleichrodt H, Pinto J. Conceptual foundations for health utility measurement. In: Jones A, editor. The Elgar Companion to Health Economics. Cheltenham: Edward Elgar Publishing Limited, 2006: 347–58

    Google Scholar 

  2. Johannesson M. The ranking properties of healthy-years equivalents and quality-adjusted life-years under certainty and uncertainty. Int J Technol Assess Health Care 1995; 11 (1): 40–8

    Article  PubMed  CAS  Google Scholar 

  3. Verschuuren M. In search of realistic QALYs for short-term pain: the standard QALY model versus holistic assessment of profiles. Chapter 2. In: Quality adjusted life years and trade off exercises: exploring methodology and validity. Ph.D thesis. Utrecht: Utrecht University, Medical Faculty, 2006 [online]. Available from URL: http://igitur-archive.library.uu.nl/dissertations/2006-0516-200032/title.pdf [Accessed 2007 Apr 15]

  4. Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 1989; 9 (2): 142–9

    Article  PubMed  CAS  Google Scholar 

  5. Johannesson M, Pliskin JS, Weinstein MC. Are healthy-years equivalents an improvement over quality-adjusted life years? Med Decis Making 1993; 13 (4): 281–6

    Article  PubMed  CAS  Google Scholar 

  6. Tsuchiya A, Dolan P. The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature. Med Decis Making 2005; 25 (4): 460–7

    Article  PubMed  Google Scholar 

  7. Bonsel G, Janssen M, Birnie E. Mild Diseases & Ailments Study (MIDAS). Ziektelastbepaling van 27 vermoedelijk ‘lichte’ ziekten ten behoeve van rationele beperking van het geneesmiddelenpakket: samenvatting. Amsterdam: Amsterdam Medical Centre, Department of Social Medicine, 2003

    Google Scholar 

  8. Brazier J, Dolan P, Karampela K, et al. Does the whole equal the sum of the parts? Patient-assigned utility scores for IBS-related health states and profiles. Health Econ 2006; 15 (6): 543–51

    Article  PubMed  Google Scholar 

  9. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23 (6): 932–46

    Article  PubMed  CAS  Google Scholar 

  10. GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. Bethesda (MD): National Institutes of Health, National Heart, Lung and Blood Institute, 2005 [online]. Available from URL: http://www.goldcopd.com [Accessed 2006 Jul 6]

  11. Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Respir Med 2004; 98 (2): 99–107

    Article  PubMed  CAS  Google Scholar 

  12. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 41 Suppl.: 46–53s

    Article  Google Scholar 

  13. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157 (5 Pt 1): 1418–22

    PubMed  CAS  Google Scholar 

  14. Aaron SD, Vandemheen KL, Clinch JJ, et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002; 121 (3): 688–96

    Article  PubMed  Google Scholar 

  15. Ruchlin HS, Dasbach EJ. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19 (6): 623–42

    Article  PubMed  CAS  Google Scholar 

  16. Rutten-van Mölken M, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3 (7): 630–4

    Article  PubMed  Google Scholar 

  17. Dolan P. Modeling valuations for the EuroQol health states. Med Care 1997; 35: 1095–108

    Article  PubMed  CAS  Google Scholar 

  18. Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006; 130 (4): 1117–28

    Article  PubMed  Google Scholar 

  19. O’Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 2007; 61 (7): 1112–20

    Article  PubMed  Google Scholar 

  20. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365 (9470): 1552–60

    Article  PubMed  CAS  Google Scholar 

  21. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. Eur Respir J 2002; 19 (2): 209–16

    Article  PubMed  CAS  Google Scholar 

  22. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19 (2): 217–24

    Article  PubMed  CAS  Google Scholar 

  23. Streiner D, Norman G. Health measurement scales: a practical guide to their development and use. Oxford: Oxford University Press, 1989

    Google Scholar 

  24. Lamers LM, Stalmeier PF, Krabbe PF, et al. Inconsistencies in TTO and VAS values for EQ-5D health states. Med Decis Making 2006; 26 (2): 173–81

    Article  PubMed  Google Scholar 

  25. Efron B, Tibshirani R. Cross-validation and other estimates of prediction error. Chapter 17. An introduction to the bootstrap. New York: Chapman & Hall, 1993

    Google Scholar 

  26. Richardson J, Hall J, Salkeld G. The measurement of utility in multiphase health states. Int J Technol Assess Health Care 1996; 12 (1): 151–62

    Article  PubMed  CAS  Google Scholar 

  27. Kuppermann M, Shiboski S, Feeny D, et al. Can preference scores for discrete states be used to derive preference scores for an entire path of events? An application to prenatal diagnosis. Med Decis Making 1997; 17 (1): 42–55

    Article  PubMed  CAS  Google Scholar 

  28. Lipscomb J. Time preference for health in cost-effectiveness analysis. Med Care 1989; 27 (3 Suppl.): S233–53

    Article  Google Scholar 

  29. MacKeigan LD, O’Brien BJ, Oh PI. Holistic versus composite preferences for lifetime treatment sequences for type 2 diabetes. Med Decis Making 1999; 19 (2): 113–21

    Article  PubMed  CAS  Google Scholar 

  30. Chapman GB. Preferences for improving and declining sequences of health outcomes. J Behav Dec Making 2000; 13: 203–18

    Article  Google Scholar 

  31. Lamers LM, McDonnell J, Stalmeier PF, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006; 15 (10): 1121–32

    Article  PubMed  CAS  Google Scholar 

  32. Borg S, Ericsson A, Wedzicha JA, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004; 7 (2): 153–67

    Article  PubMed  Google Scholar 

  33. Oostenbrink JB, Rutten-van Molken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8 (1): 32–46

    Article  PubMed  Google Scholar 

  34. Hoogendoorn M, Feenstra T, Hoogenveen R, et al. A health policy model for COPD: effects of smoking cessation. Rotterdam: iMTA, Erasmus MC, 2003 Nov

    Google Scholar 

  35. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23 (6): 619–37

    Article  PubMed  CAS  Google Scholar 

  36. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004; 116 (5): 325–31

    Article  PubMed  CAS  Google Scholar 

  37. Pickard AS, Kohlmann T, Janssen MF, et al. Evaluating equivalency between response systems: application of the Rasch model to a 3-level and 5-level EQ-5D. Med Care 2007; 45 (9): 812–9

    Article  PubMed  Google Scholar 

  38. Miller G. The magic number seven, plus or minus two: some limits in our capacity for processing information. Psychol Rev 1956; 63 (2): 81–97

    Article  PubMed  CAS  Google Scholar 

  39. Greiner W, Weijnen T, Nieuwenhuizen M, et al. A European EQ-5D VAS valuation set. In: Brooks R, Rabin R, De Charro F, editors. The measurement and valuation of health status using EQ-5D: a European perspective. Dordrecht: Kluwer Academic, 2003: 143–65

    Google Scholar 

  40. Revicki DA, Leidy NK, Brennan-Diemer F, et al. Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index. Qual Life Res 1998; 7 (8): 693–702

    Article  PubMed  CAS  Google Scholar 

  41. Revicki DA, Leidy NK, Brennan-Diemer F, et al. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest 1998; 114 (4): 998–1007

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Financial support for this study was provided by Boehringer Ingelheim International and Pfizer Global Pharmaceuticals. The funding agreement ensured the authors’ independence in designing the study, interpreting the data and writing and publishing the report. The authors would particularly like to thank Prof. Dr Gouke Bonsel for his advice in constructing the profiles and designing the study, and Mr Joost van der Burgh, Prof. Dr Miel Wouters and Dr Niels Chavannes for advice on the chronic obstructive pulmonary disease profile descriptions. We would also like to thank all the respondents who participated in this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Erasmus MC, Institute for Medical Technology Assessment (iMTA), P.O. Box 1738, 3000, DR Rotterdam, the Netherlands

    Maureen P. M. H. Rutten-van Mölken, Martine Hoogendoorn & Leida M. Lamers

Authors
  1. Maureen P. M. H. Rutten-van Mölken
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martine Hoogendoorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leida M. Lamers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maureen P. M. H. Rutten-van Mölken.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rutten-van Mölken, M.P.M.H., Hoogendoorn, M. & Lamers, L.M. Holistic Preferences for 1-Year Health Profiles Describing Fluctuations in Health. Pharmacoeconomics 27, 465–477 (2009). https://doi.org/10.2165/00019053-200927060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200927060-00003

Keywords

Search

Navigation